Phase II Trials of Single Agent Anti-VEGF Therapy for Patients with Chronic Lymphocytic Leukemia (CLL)
- Citation:
- Leuk Lymphoma vol 51 (12) 2222-2229
- Year:
- 2010
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- N01CM62205, N01-CM62207, N01 CM062205, U24 CA114740, CA113408, N01-CM62205, CA114740, P30 CA015083, CA25224, N01CM62207, CA116237, K23 CA113408, U10 CA025224, N01 CM062207, R01 CA116237, N01 CA015083
- Corr. Author:
- Authors:
- Tait Shanafelt Clive Zent John Byrd Charles Erlichman Betsy LaPlant Asish Ghosh Timothy Call Miguel Villalona-Calero Diane Jelinek Deborah Bowen Kristina Laumann Wenting Wu Curtis Hanson Neil Kay
- Networks:
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- NCCTG-N048F, NCCTG-N0683
- Phases:
- 2
- Keywords:
- chronic lymphocytic leukemia, angiogenesis, vascular endothelial growth factor (VEGF), therapy, bevacizumab, receptor tyrosine kinase inhibitor